Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease

被引：57

作者：

Kawabata, Hiroshi ^{[1
]}

Tomosugi, Naohisa ^{[2
]}

Kanda, Junya ^{[1
]}

Tanaka, Yasuhiro ^{[1
]}

Yoshizaki, Kazuyuki ^{[3
]}

Uchiyama, Takashi ^{[1
]}

机构：

[1] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto 6068507, Japan

[2] Kanazawa Med Univ, Med Res Inst, Div Adv Med, Prote Res Unit, Uchinada, Ishikawa 9200293, Japan

[3] Osaka Univ, Grad Sch Med, Dept Clin Immunol, Suita, Osaka 5650871, Japan

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 06期

关键词：

Castleman's disease; Hepcidin; Interleukin-6; Iron metabolism; Tocilizumab;

D O I：

10.3324/haematol.10794

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report two cases of multicentric Castleman's disease (MCD) whose serum hepcidin levels were rapidly down-regulated by administration of tocilizumab, an anti-interleukin 6 (IL-6) receptor antibody. Our results indicate that IL-6-induced hepcidin over-production may be involved in the pathophysiology of microcytic anemia commonly observed in this disease.

引用

页码：857 / 858

页数：2

共 10 条

[1] Hepcidin - a regulator of intestinal iron absorption and iron recycling by macrophages [J].

Ganz, T .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (02) :171-182

[2]

Hirano T, 1989, Prog Growth Factor Res, V1, P133, DOI 10.1016/0955-2235(89)90007-0

[3] A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease [J].

Ito, H ;

Takazoe, M ;

Fukuda, Y ;

Hibi, T ;

Kusugami, K ;

Andoh, A ;

Matsumoto, T ;

Yamamura, T ;

Azuma, J ;

Nishimoto, N ;

Yoshizaki, K ;

Shimoyama, T ;

Kishimoto, T .

GASTROENTEROLOGY, 2004, 126 (04) :989-996

[4] Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS [J].

Kemna, E ;

Pickkers, P ;

Nemeth, E ;

van der Hoeven, H ;

Swinkels, D .

BLOOD, 2005, 106 (05) :1864-1866

[5] Regulation of hepcidin transcription by interleukin-1 and interleukin-6 [J].

Lee, P ;

Peng, HF ;

Gelbart, T ;

Wang, L ;

Beutler, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (06) :1906-1910

[6] Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein [J].

Nemeth, E ;

Valore, EV ;

Territo, M ;

Schiller, G ;

Lichtenstein, A ;

Ganz, T .

BLOOD, 2003, 101 (07) :2461-2463

[7] Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease [J].

Nishimoto, N ;

Kanakura, Y ;

Aozasa, K ;

Johkoh, T ;

Nakamura, M ;

Nakano, S ;

Nakano, N ;

Ikeda, Y ;

Sasaki, T ;

Nishioka, K ;

Hara, M ;

Taguchi, H ;

Kimura, Y ;

Kato, Y ;

Asaoku, H ;

Kumagai, S ;

Kodama, F ;

Nakahara, H ;

Hagihara, K ;

Yoshizaki, K ;

Kishimoto, T .

BLOOD, 2005, 106 (08) :2627-2632

[8] Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System [J].

Tomosugi, Naohisa ;

Kawabata, Hiroshi ;

Wakatabe, Rumi ;

Higuchi, Masato ;

Yamaya, Hideki ;

Umehara, Hisanori ;

Ishikawa, Isao .

BLOOD, 2006, 108 (04) :1381-1387

[9] Fifty years of multicentric Castleman's disease [J].

Waterston, A ;

Bower, M .

ACTA ONCOLOGICA, 2004, 43 (08) :698-704

[10]

YOSHIZAKI K, 1989, BLOOD, V74, P1360

← 1 →